These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24378596)

  • 1. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease.
    de Bruyn M; Machiels K; Vandooren J; Lemmens B; Van Lommel L; Breynaert C; Van der Goten J; Staelens D; Billiet T; De Hertogh G; Ferrante M; Van Assche G; Vermeire S; Opdenakker G; Schuit F; Rutgeerts P; Arijs I
    Inflamm Bowel Dis; 2014 Feb; 20(2):339-52. PubMed ID: 24378596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease.
    Meijer MJ; Mieremet-Ooms MA; van Duijn W; van der Zon AM; Hanemaaijer R; Verheijen JH; van Hogezand RA; Lamers CB; Verspaget HW
    Inflamm Bowel Dis; 2007 Feb; 13(2):200-10. PubMed ID: 17206679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF-α in the mucosa of patients with inflammatory bowel diseases.
    Franzè E; Caruso R; Stolfi C; Sarra M; Cupi ML; Ascolani M; Sedda S; Antenucci C; Ruffa A; Caprioli F; MacDonald TT; Pallone F; Monteleone G
    Inflamm Bowel Dis; 2013 Mar; 19(3):501-11. PubMed ID: 23429442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
    Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
    Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.
    Arijs I; De Hertogh G; Lemaire K; Quintens R; Van Lommel L; Van Steen K; Leemans P; Cleynen I; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
    PLoS One; 2009 Nov; 4(11):e7984. PubMed ID: 19956723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease.
    Su J; Chen T; Ji XY; Liu C; Yadav PK; Wu R; Yang P; Liu Z
    Inflamm Bowel Dis; 2013; 19(4):720-8. PubMed ID: 23429464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium.
    Pedersen G; Saermark T; Kirkegaard T; Brynskov J
    Clin Exp Immunol; 2009 Feb; 155(2):257-65. PubMed ID: 19137636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
    Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
    Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.
    Veltkamp C; Anstaett M; Wahl K; Möller S; Gangl S; Bachmann O; Hardtke-Wolenski M; Länger F; Stremmel W; Manns MP; Schulze-Osthoff K; Bantel H
    Gut; 2011 Oct; 60(10):1345-53. PubMed ID: 21459928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-α-induced down-regulation of CDX2 suppresses MEP1A expression in colitis.
    Coskun M; Olsen AK; Holm TL; Kvist PH; Nielsen OH; Riis LB; Olsen J; Troelsen JT
    Biochim Biophys Acta; 2012 Jun; 1822(6):843-51. PubMed ID: 22326557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis.
    Chitul A; Voiosu AM; Marinescu M; Caraiola S; Nicolau A; Badea GC; Pârvu MI; Ionescu RA; Mateescu BR; Voiosu MR; Băicuş CR; Rimbaş M
    Rom J Intern Med; 2017 Mar; 55(1):44-52. PubMed ID: 28103201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns Disease.
    Sena A; Grishina I; Thai A; Goulart L; Macal M; Fenton A; Li J; Prindiville T; Oliani SM; Dandekar S; Goulart L; Sankaran-Walters S
    PLoS One; 2013; 8(10):e76969. PubMed ID: 24130820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
    Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
    Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
    West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
    Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease.
    Bhol KC; Tracey DE; Lemos BR; Lyng GD; Erlich EC; Keane DM; Quesenberry MS; Holdorf AD; Schlehuber LD; Clark SA; Fox BS
    Inflamm Bowel Dis; 2013 Oct; 19(11):2273-81. PubMed ID: 23949620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.